Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (SCT-NMO)
Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica
Sponsor: University of Calgary
Terminated
recruitment failure
Other terminated trials from University of Calgary
Other Neuromyelitis Optica trials with similar outcome
This PHASE1/PHASE2 trial investigates Neuromyelitis Optica and is currently terminated or withdrawn. University of Calgary leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .